Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(54)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
HT-29 M2jwcGN6fG:2b4jpZ{BCe3OjeR?= NYHQco97OTBibl2= M3LROlczKGh? NGf2bWhFVVOR NVPSSpp1WG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6
HT-29 MnHzR5l1d3SxeHnjJGF{e2G7 MYWxNEBvVQ>? MlvkO|IhcA>? MVrEUXNQ Mlj5VI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7
HT-29 NXPabmNxS3m2b4TvfIlkKEG|c3H5 NIPoZYMyOCCwTR?= NVn1Vm84PzJiaB?= NFzkOGJFVVOR MVnQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=>
PC3 MXPLbY5ie2ViQYPzZZk> NXnTNlJTOTByIH7N NXrY[ZhnOSCq MULEUXNQ MnXoVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6=
PC3 M{PKZ2tqdmG|ZTDBd5NigQ>? MVOxNFAhdk1? NX\tTJZOOSCq MlfqSG1UVw>? M2PWWWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w
PC3 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\lV3cyNjVizszN MWixJIg> NHqzd4dFVVOR Mn\KTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P
HEK293 Mn\VSpVv[3Srb36gRZN{[Xl? Mo\ZNVAxKG6P NIG4Slg5KGh? MYXEUXNQ M124NGlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?=
BT-20 MXPLbY5ie2ViQYPzZZk> NEDZUGMzOCEQvF2= NUntUJB7TE2VTx?= NXjZbXRGTG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36=
U937 MVTBcpRq[mGldHXybYFtKEG|c3H5 NUnjfYg3PTBizszN MYm0PEBp MULEUXNQ NH\mTGNKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO=
U937 NG\jN|NCdnSrYnHjeIVzcWGuIFHzd4F6 M1PSUlUxKM7:TR?= MlfROFghcA>? Mk\PSG1UVw>? MmHISI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>?
U937 M37mbmFvfGmkYXP0[ZJq[WxiQYPzZZk> M3m4bFUxKM7:TR?= NFHhSHc1QCCq NEm0S4FFVVOR MnnCSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM>
MCF-7 M1\YW2F2fG:yaHHnfUBCe3OjeR?= NHy2fJc{OCCwTR?= M{HUZVQhcA>? NXfSdph6TE2VTx?= NX3xVpBQUW6mdXPld{BifXSxcHjh[5k>
U87MG NFrWZZZMcW6jc3WgRZN{[Xl? NX;aZldkOSEQvF2= MWW2JIg> MWPEUXNQ MXTQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>?
U87MG NGi0SG5McW6jc3WgRZN{[Xl? NVG5SW1lOSEQvF2= M{PxPFYhcA>? NV7pc3cyTE2VTx?= M4raSHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u
U87MG M37NOmtqdmG|ZTDBd5NigQ>? MUexJO69VQ>? MUi2JIg> M2TYOWROW09? M1nvWWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w
U87MG NVHnSGN7U2mwYYPlJGF{e2G7 MYGxJO69VQ>? NUfLb4JqPiCq NXK3UJZiTE2VTx?= MkjOSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v
COS7 cells expressing EGFP-HDQ74/rheb NIPuNppCfXSxcHjh[5khSXO|YYm= MnvKNE4zKM7:TR?= M3PxR|I1KGh? NHTQN2pFVVOR MlzXTY5lfWOnczDheZRweGijZ4m=
COS7 cells expressing EGFP-LC3 MoPMRZV1d3CqYXf5JGF{e2G7 NUnmUnZCOC5{IN88US=> MUeyOEBp M2LZfGROW09? NGXVPZdKdmS3Y3XzJIF2fG:yaHHnfS=>
H4 MUDGeY5kfGmxbjDBd5NigQ>? M4T0V|AvOiEQvF2= MXyyOEBp MUTEUXNQ NGjq[mtKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{
HeLa NULsVZl5TnWwY4Tpc44hSXO|YYm= NGrZSnQyODBibl2= M4nFS|M3KGh? NYjW[lY2TE2VTx?= MXLJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u
HeLa NGHBZZRHfW6ldHnvckBCe3OjeR?= M1HLcFExOCCwTR?= NESwSYQ{PiCq M1TUXmROW09? NH3MOVBKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25?
HeLa MonmSpVv[3Srb36gRZN{[Xl? Moq5NVAxKG6P MkG3N|YhcA>? Mnn3SG1UVw>? M{PYN2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=>
SYF MXjGeY5kfGmxbjDBd5NigQ>? M2\3cFExOCCwTR?= MUSyOEBp MVLEUXNQ NHXYfndKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44>
SYF MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjneJhLOTByIH7N MXKyOEBp MX3EUXNQ NHjPb|ZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz
HEK293T M1XqPWFvfGm4aYLhcEBCe3OjeR?= NF7uTlAyKG6P NWrL[IN7PCCm NHfDSplFVVOR M{HhcWlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N
HEK293T NG\hXmxCdnSrdnnyZYwhSXO|YYm= NUDZSZluOSCwTR?= MnWxOEBl M1XhSWROW09? NVjJc5ExUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0>
PBMC M2\RNWZ2dmO2aX;uJGF{e2G7 MV[xJI5O NGf6[lcyPCCm MWLEUXNQ MUnS[YR2[2W|IFPDVlUh\GWwc3n0fS=>
PBMC NWHjc4YxTnWwY4Tpc44hSXO|YYm= M4fqW|Ehdk1? NYXX[4ZMOTRiZB?= NV75RpVoTE2VTx?= MXvEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=>
HEK293 cells Ml\1T4lv[XOnIFHzd4F6 MXy1NEBvVQ>? NUfJUYJ[PDVibXnu NFu0WlNFVVOR M{nFfGlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1?
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MmriSpVv[3Srb36gRZN{[Xl? M3\VNlExOCCwTR?= NXfPVoJnPCCq M3;zc2ROW09? MlfuTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM>
Human mixed lymphocyte NXLKNmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHj[mk2KG6P M{HYfGROW09? M3fSe2lEPTB;MT62JI5ONg>?
Lewis rat lymph node cells M2[yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq1JO69VQ>? MYnEUXNQ NULnbWY6UUN3ME2yMlYh|ryP
cells from the thymus of normal BALB/c mice MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX22c5V[OTBibl2= NY\5bndVPzJiaB?= MXHEUXNQ NHT5NGJKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N
MRK-nu-1 M1:0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\2NWlEPTB;MD64OFUheE1?
OCUB-M M1T1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW0RoZKSzVyPUWuNlQheE1?
SF539 NGHE[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvwTWM2OD1zMT62JJBO
ES4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki3TWM2OD1{MT61JJBO
RL95-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PK[GlEPTB;MUC3JJBO
LC-2-ad NVHSWGpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFVJlYUUN3ME20NlMheE1?
Daudi NIf3[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TpdGlEPTB;NEO0JJBO
NTERA-S-cl-D1 NEXDTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHuTWM2OD12NEOgdG0>
OS-RC-2 M1TCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTISY5KSzVyPU[1NkBxVQ>?
VA-ES-BJ M1PYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG1TWM2OD15MkOgdG0>
GR-ST NFnZe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfPPHVKSzVyPUi0OkBxVQ>?
SW872 NV3JbWxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTh2NjDwUS=>
NOS-1 M3X4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfZTWM2OD16N{GgdG0>
MC116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXezZ|IzUUN3ME25PFUheE1?
NCI-H1355 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnMTWM2OD1zLkCxJI5O
RPMI-8226 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfaSohqUUN3ME2xMlE6KG6P
TE-15 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jLPGlEPTB;MT6zOkBvVQ>?
Ramos-2G6-4C10 NXn0cG54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwNE[gcm0>
KU812 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm1[GV1UUN3ME2yMlAyKG6P
EW-1 NI[1Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS0cJpXUUN3ME2yMlE4KG6P
KS-1 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwNEWgcm0>
SK-LMS-1 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfyUlVKSzVyPUKuOFkhdk1?
TGBC1TKB M3rib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W4TmlEPTB;Mj62PUBvVQ>?
TE-6 M4jkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwN{egcm0>
ETK-1 NHnVcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwOEKgcm0>
BE-13 M1T6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;XTWM2OD1{Lkm5JI5O
A3-KAW M3nPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfhTWM2OD1{Lkm5JI5O
TE-10 NV6zV|JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC4cm85UUN3ME2zMlMhdk1?
DOHH-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwM{Wgcm0>
ES6 NIrYW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXqXlNKSzVyPUOuOFMhdk1?
OPM-2 NETzNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETY[|hKSzVyPUSuNVUhdk1?
SH-4 M3THemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XPVGlEPTB;ND6zOEBvVQ>?
NB13 M4fNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXuZ5pXUUN3ME20MlM3KG6P
HUTU-80 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX4TWM2OD12LkSyJI5O
CCRF-CEM NXTuV5A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG3TWM2OD12Lkm0JI5O
TGBC24TKB NV:3WJJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\tbpEzUUN3ME21MlUyKG6P
697 M2jJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTZwMkigcm0>
J-RT3-T3-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{eyTWlEPTB;Nj60OkBvVQ>?
KALS-1 NFHS[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36zbGlEPTB;Nj61OkBvVQ>?
no-10 M1fxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLJTWM2OD15LkK5JI5O
SK-NEP-1 M361Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCNmlEPTB;OD63PUBvVQ>?
L-540 M3K4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT1S2VKSzVyPUGwMlQzKG6P
JiyoyeP-2003 NYHxRnFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFyLkm0JI5O
HH NXSwbGc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDKWIdKSzVyPUGxMlM6KG6P
SR NWXN[FdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjjZ41KSzVyPUGxMlQ2KG6P
QIMR-WIL MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFzLki1JI5O
A4-Fuk MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HiVGlEPTB;MUOuNVIhdk1?
CESS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF|LkGzJI5O
KE-37 NHeyTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDTUnpKSzVyPUG2MlA4KG6P
SK-UT-1 M2Hjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f4bWlEPTB;MU[uPFEhdk1?
SIG-M5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvy[3lbUUN3ME2xO{4zPSCwTR?=
HT M1S3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rMNWlEPTB;MUeuOkBvVQ>?
DEL Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfle21nUUN3ME2xO{46QSCwTR?=
SK-PN-DW MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfJTWM2OD1{MD6yN{BvVQ>?
RPMI-8402 NVzJWJZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm4TWM2OD1{MT63O{BvVQ>?
RPMI-6666 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ2LkSyJI5O
NCI-H720 NVrUT3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ3LkSxJI5O
EW-16 NXPNRohIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ4Lki3JI5O
BL-70 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ6LkO4JI5O
SF126 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNyLkO4JI5O
BC-1 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL6TWM2OD1|MT6yOkBvVQ>?
MHH-PREB-1 NEDnTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LkT2lEPTB;M{KuOFQhdk1?
A101D M{L1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTN{Lk[yJI5O
NMC-G1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFztNVdKSzVyPUOzMlY4KG6P
LB1047-RCC MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTZTWM2OD1|ND62PUBvVQ>?
EM-2 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK5TWM2OD1|OD61N{BvVQ>?
COLO-684 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LKO2lEPTB;M{muPEBvVQ>?
Becker NUDZSZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S2SGlEPTB;NEGuNFUhdk1?
BL-41 NESzUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7STWM2OD12Mz62OkBvVQ>?
MDA-MB-134-VI Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ETWM2OD12ND6wNkBvVQ>?
L-363 NEXF[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[5V5pKSzVyPUS0Mlc{KG6P
ECC4 NG\UNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nhWGlEPTB;NESuO|ghdk1?
A388 M1GxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zjbGlEPTB;NESuPFIhdk1?
HEL MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTITWM2OD12OT63PUBvVQ>?
RKO M4PJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTVyLkK5JI5O
KINGS-1 NV\4Nmt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLFVoNKSzVyPUWxMlU2KG6P
EB-3 NXTDRWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorTTWM2OD13Mj62O{BvVQ>?
ARH-77 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDxZpdKSzVyPUWyMlghdk1?
GCIY MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi5WVg3UUN3ME21N{41PiCwTR?=
NCI-H1304 Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP4UnJKSzVyPUW3MlIzKG6P
KARPAS-299 NWTIcWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTZzLkiyJI5O
IA-LM Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjyTWM2OD14OD6xN{BvVQ>?
GI-1 NWT4U|duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC5[o9KSzVyPUewMlM6KG6P
TE-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\qTWM2OD15Nz6xO{BvVQ>?
LS-411N MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzXRmt4UUN3ME23O{42PyCwTR?=
no-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTh|LkK0JI5O
MV-4-11 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTNTWM2OD16Mz63N{BvVQ>?
BV-173 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz4TWM2OD16Mz65O{BvVQ>?
CMK M3u0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqxdVA5UUN3ME24OE4yPiCwTR?=
LC4-1 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO2OHl6UUN3ME24Ok44OiCwTR?=
COR-L279 NHPLVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17wWGlEPTB;OEeuNlUhdk1?
NCI-H209 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vYPWlEPTB;OEeuOFEhdk1?
Raji NVnadZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T6fGlEPTB;OEmuO|Ihdk1?
LB996-RCC M2rPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYqyXVMzUUN3ME25N{41OyCwTR?=
NCI-H526 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjmXZY{UUN3ME25N{42QSCwTR?=
KGN NHTwOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTl4LkK5JI5O
MOLT-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\meoJKSzVyPUm2Mlc6KG6P
PF-382 NI\BS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXSTWM2OD17Nj63PUBvVQ>?
BC-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnjPHRPUUN3ME25PU4yQCCwTR?=
KARPAS-422 NUfYd2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[4TWM2OD1zMEKuNFkhdk1?
SBC-1 M{S1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWxS3RKSzVyPUGwO{44PSCwTR?=
LC-1F MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrxTWM2OD1zMEiuNFUhdk1?
GB-1 NVTrfYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzGXWJnUUN3ME2xNFkvODJibl2=
SNB75 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT4ZWNXUUN3ME2xNVkvPjlibl2=
BB65-RCC M4fJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:0fVBKSzVyPUGxPU46OyCwTR?=
NCI-N87 NYDobZRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF{MT65PEBvVQ>?
IST-MEL1 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUeyUol5UUN3ME2xNlIvOzhibl2=
HOP-62 NUTBdXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzrcItOUUN3ME2xNlYvQDlibl2=
ACN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P0SmlEPTB;MUS2Mlc2KG6P
DMS-114 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6zOVlLUUN3ME2xOVAvPjdibl2=
MLMA NHXleZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7KUmdYUUN3ME2xOVkvQDhibl2=
HT-144 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH5R4hNUUN3ME2xOlUvPDNibl2=
C2BBe1 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXId|NKSzVyPUG2O{44PiCwTR?=
L-428 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL5TWM2OD1zN{euO{BvVQ>?
DU-4475 MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLi[Y1KSzVyPUG4O{43QCCwTR?=
CP67-MEL MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnxTWM2OD1zOUmuN|ghdk1?
MEG-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP1cZkxUUN3ME2yNFEvQTZibl2=
IST-SL2 M{X6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33afGlEPTB;MkC4MlY{KG6P
ES8 NWHnRYVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ{NT65OEBvVQ>?
COLO-800 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ|NT6yPEBvVQ>?
MFH-ino M1jn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CzRmlEPTB;MkO1Mlg1KG6P
OVCAR-4 NGGzWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFToOnBKSzVyPUKzO{4zPCCwTR?=
PSN1 M{TLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4bWlEPTB;MkSyMlcyKG6P
EW-12 NGTQR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP6OXlpUUN3ME2yOFMvOSCwTR?=
HCC1599 NWDZT2d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TibGlEPTB;Mk[xMlQ4KG6P
SJSA-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL6TWM2OD1{N{GuOFYhdk1?
ST486 M4LBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ7Nj6xOEBvVQ>?
NOMO-1 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnETWM2OD1|MECuNlEhdk1?
MN-60 M4Do[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KzbGlEPTB;M{C1MlMzKG6P
HCC1187 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDndZlKSzVyPUOwO{4zPSCwTR?=
SW982 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNzND63OUBvVQ>?
LB647-SCLC NWTvd49{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3qS29sUUN3ME2zNlgvPzFibl2=
HC-1 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\TZmZKSzVyPUOzOU42KG6P
EHEB NUfXPFRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN|Nz61NkBvVQ>?
TUR M2HiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPCVXN5UUN3ME2zOlMvQTVibl2=
LU-139 M3HETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTrc4NKSzVyPUO3PE4xOiCwTR?=
NB1 M3PmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rJ[mlEPTB;M{i0MlQ2KG6P
BB30-HNC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnsTWM2OD1|OEiuN|Ihdk1?
HAL-01 NYHyc2t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTN6OT6yOkBvVQ>?
K5 M1\pcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\jVFNKSzVyPUSxNU4{PyCwTR?=
MZ2-MEL NIfIOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRzMz62OEBvVQ>?
RXF393 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jTbWlEPTB;NEG2MlQ2KG6P
NCI-H1648 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO4eXJPUUN3ME20NVcvPTNibl2=
TE-12 NInYUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDoTWM2OD12M{SuNlYhdk1?
EoL-1- NIfYZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3x[ZhKSzVyPUSzO{46QCCwTR?=
JAR Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXtWpFKSzVyPUSzPE43OiCwTR?=
DSH1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR3OD65NUBvVQ>?
NCI-H187 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXSSYdKSzVyPUS2Nk45OSCwTR?=
HCE-4 M2fVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfLTWM2OD12N{euOlYhdk1?
8-MG-BA Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD1T5dKSzVyPUW4NU42OiCwTR?=
KLE NX;rbI1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTV6NT6yJI5O
KNS-42 NFjwSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2ydnp[UUN3ME21PFYvQDFibl2=
MSTO-211H NVrFXZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTZyOT63OEBvVQ>?
GDM-1 M{TEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;ZbHVKSzVyPU[xOE4xQSCwTR?=
TE-1 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO2R3ZKSzVyPU[0Ok4yOiCwTR?=
BT-474 NV7WbGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnVd2ZpUUN3ME22OFcvODZibl2=
KARPAS-45 NU\vOFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljDTWM2OD14NEeuOkBvVQ>?
MOLT-16 NVrwW3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGCxXVRKSzVyPU[0O{46OyCwTR?=
KURAMOCHI NYrrRWpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDoSpQ6UUN3ME22OVcvPTFibl2=
K-562 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3yTWM2OD14NkmuOVEhdk1?
EKVX MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTZ5Mj63NUBvVQ>?
GAK MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZ5NT6zJI5O
NCI-SNU-5 NHWycphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXtZWlKSzVyPU[5NE4xOSCwTR?=
NCI-H2126 NVTtcpJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C0cmlEPTB;N{K2Mlg4KG6P
CTV-1 NHvUcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTd2ND65JI5O
SW962 NUfFbmh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTd2OD60OEBvVQ>?
MONO-MAC-6 M4nIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHlUmZKSzVyPUe1Ok46OyCwTR?=
NCI-H748 NGfkRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrYfIxKSzVyPUe1PE46QSCwTR?=
NCI-H524 NGHYWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTd6MD63N{BvVQ>?
LS-123 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\JUGJKSzVyPUe5OU43QSCwTR?=
NB7 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRThzND6xOEBvVQ>?
LS-1034 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTh{OD65PEBvVQ>?
TE-5 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PlV2lEPTB;OEizMlU3KG6P
A704 NF7tbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4noR2lEPTB;OEm5MlE2KG6P
TK10 NF;uS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL5c3pvUUN3ME25NVYvODNibl2=
NCI-H345 NELHdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTl2Mz6yNkBvVQ>?
CGTH-W-1 M1j6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj1bYdrUUN3ME25OFgvOTNibl2=
NCI-H510A MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzUUlVKSzVyPUm4OU4yOiCwTR?=
NCI-H1963 NGKyfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPXTWM2OD1zLkCzNlkzKM7:TR?=
SCC-3 NYTOcIpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfDTWM2OD1zLkCzOFE1KM7:TR?=
EW-11 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT3ZllRUUN3ME2xMlA5PzR|IN88US=>
CPC-N MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fDW2lEPTB;MT6wPFgh|ryP
NCI-H1417 NWT1dJZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqwdlJKSzVyPUGuNVIzPiEQvF2=
DG-75 NH7CZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITRWoVKSzVyPUGuNVYzQDVizszN
HD-MY-Z M3rDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rLb2lEPTB;MT6xOlQyPiEQvF2=
ATN-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwMk[yNFkh|ryP
KM-H2 NF[zW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\FO|g1UUN3ME2xMlI3PDB6IN88US=>
NCI-H2081 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwMk[2N|ch|ryP
HL-60 NXjrcnp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTsTWM2OD1zLkK2PVU6KM7:TR?=
DB NYXTcHU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPyfoFKSzVyPUGuNlczPDJizszN
NCI-H1522 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7qTWM2OD1zLkK4PFg4KM7:TR?=
AM-38 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwM{C3NkDPxE1?
NCI-H446 M4OxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\uOGlEPTB;MT6zNlEzOSEQvF2=
SU-DHL-1 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPITWM2OD1zLkOyPFAyKM7:TR?=
NH-12 NYrZSGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm0TWM2OD1zLkO2N|c1KM7:TR?=
DMS-79 NYjCOlNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[4Ro1KSzVyPUGuN|Y5PjZizszN
NCI-H716 NYnkPXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m2WGlEPTB;MT6zPFk5PiEQvF2=
ML-2 NISzSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPBdIRQUUN3ME2xMlQyPTJ7IN88US=>
NB10 NVnWOFRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu4TWM2OD1zLkS2OlMzKM7:TR?=
ONS-76 NUnUO2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7MeYNbUUN3ME2xMlU{PTZ7IN88US=>
LOUCY NFLqZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwNUS2OVch|ryP
SCLC-21H MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwNUi1PFIh|ryP
TGW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Ox[2lEPTB;MT62N|k4PSEQvF2=
LXF-289 NUfLdohjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvPTWM2OD1zLkezNlY5KM7:TR?=
BB49-HNC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PxOGlEPTB;MT63N|U5PiEQvF2=
NCI-H747 NXLCZWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfITWM2OD1zLke1N|Q3KM7:TR?=
LU-165 NWToUYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWyUJZKSzVyPUGuPFQ6QDZizszN
OMC-1 NXvx[JNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwOUWwOlYh|ryP
RCC10RGB NGPa[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\HTWM2OD1zLkm1PFE4KM7:TR?=
SW684 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LIN2lEPTB;MT65OlA6QSEQvF2=
TE-8 M2HiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwMEW1OVkh|ryP
SK-N-DZ M{KxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDXTWM2OD1{LkGzNlc1KM7:TR?=
EVSA-T MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfTSVhZUUN3ME2yMlE4OzF3IN88US=>
KASUMI-1 NG\ZdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HPU2lEPTB;Mj6xPFgyPSEQvF2=
NKM-1 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwMkW0O|Ih|ryP
CAL-148 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7FTWM2OD1{LkOzOlE1KM7:TR?=
NCI-H64 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwM{SyN|Ih|ryP
KNS-81-FD MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\rTWM2OD1{LkO2OlIh|ryP
KM12 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S1Z2lEPTB;Mj60NFg{QSEQvF2=
SW954 NYXIeZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\keZVKSzVyPUKuOFc4PzlizszN
NCI-H1395 NHHZZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GxXWlEPTB;Mj61NlY1PSEQvF2=
DJM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjmOFNKSzVyPUKuOlA3OyEQvF2=
COLO-668 NITRNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJwOEK2PVUh|ryP
NCI-H1436 NVr6T3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJwOEW2NVUh|ryP
LB2241-RCC MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHzTWM2OD1{Lki2PFM6KM7:TR?=
GT3TKB NIDpb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL3[JpKSzVyPUKuPFkxPTVizszN
COLO-824 NEPHUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLKe45KSzVyPUKuPFk4PjhizszN
ES1 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TpUmlEPTB;Mj64PVg4QSEQvF2=
LB771-HNC NVXXUnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvyTWM2OD1{LkmwPVQ3KM7:TR?=
GI-ME-N NGf0Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jLdGlEPTB;Mz6wNFkxPCEQvF2=
NALM-6 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jXNGlEPTB;Mz6wNFk{OyEQvF2=
LU-134-A Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;OZWxKSzVyPUOuNFU1OjVizszN
DMS-153 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTNwMEW4NlQh|ryP
MZ1-PC NXz4WlU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwMEmwO|gh|ryP
NCI-H1155 NWDoRldiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXRb45KSzVyPUOuNVE3OSEQvF2=
CAS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwMUO3NFch|ryP
D-502MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M12zZmlEPTB;Mz6xOFM6KM7:TR?=
NCI-H2141 NFzqPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwMUe0OVIh|ryP
NB6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32yemlEPTB;Mz6xPFI2QSEQvF2=
NCCIT MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;iTWM2OD1|LkKxPFA6KM7:TR?=
NB69 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwM{G4PVEh|ryP
JVM-2 M321SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWzUpc6UUN3ME2zMlM3PDN|IN88US=>
K052 NUTvOnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwM{e5Olgh|ryP
HCC2157 M4fqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLCUGhKSzVyPUOuOVMzOjhizszN
KMOE-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf5TWM2OD1|LkW0NlQzKM7:TR?=
SF268 NWnMXHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonDTWM2OD1|LkexOVU1KM7:TR?=
CHP-126 NEOz[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTNwN{[0OVgh|ryP
CP66-MEL NYPjfGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX1TWM2OD1|Lke5NFk1KM7:TR?=
NCI-H69 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPxTWM2OD12LkCxPVM3KM7:TR?=
A253 M2nvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTRwMEKxNFEh|ryP
NB14 M4TPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjLeW5KSzVyPUSuNVA1PzlizszN
NCI-H1694 M2LrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\JW2lEPTB;ND6xN|EyOiEQvF2=
NCI-H2196 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGyWIdKSzVyPUSuNVcyPjlizszN
TE-9 NYL5Npl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPkTWM2OD12LkG3OVgzKM7:TR?=
D-283MED M3v6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXFVoVPUUN3ME20MlE5QDRizszN
OCI-AML2 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRwMUm0PFkh|ryP
D-263MG M3f5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwMkK5OlEh|ryP
MPP-89 NFvvbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnlfYh{UUN3ME20MlI4OzB2IN88US=>
LAMA-84 NHq1PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GyU2lEPTB;ND6zNFQzOSEQvF2=
LB373-MEL-D M4Dre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ntPWlEPTB;ND6zOlc5QSEQvF2=
UACC-257 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHwe|RlUUN3ME20MlM6PTN2IN88US=>
MC-CAR NWjNdGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nkTmlEPTB;ND60N|k6KM7:TR?=
COLO-320-HSR M2LoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf2UHlKSzVyPUSuOFQ1OjdizszN
P30-OHK MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\rTWM2OD12Lk[2OVgyKM7:TR?=
UACC-812 NVzsXmdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Q[WlEPTB;ND62PVE3OSEQvF2=
CTB-1 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD5dY5KSzVyPUSuO|E2PTVizszN
ALL-PO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRwOESwO|ch|ryP
SK-MEL-2 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\RcWlEPTB;ND64Olk2PSEQvF2=
TC-YIK NFWzb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfnXY5KSzVyPUSuPVc6PDJizszN
NCI-H1882 NFzwZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfBcWhsUUN3ME21MlAzODBzIN88US=>
MHH-CALL-2 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPvb3UxUUN3ME21MlA2ODR{IN88US=>
U-87-MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jrd2lEPTB;NT6wPVQ3PiEQvF2=
NCI-H1092 NFTjWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H2U2lEPTB;NT6yOlU2PSEQvF2=
TE-441-T MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq1O3V1UUN3ME21MlI4QDJizszN
SK-MEL-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTVwMkmwOFQh|ryP
EW-22 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrVTWM2OD13LkK5OFY3KM7:TR?=
MZ7-mel MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;RTWM2OD13LkSwOlkyKM7:TR?=
LP-1 NGDwSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TEZmlEPTB;NT60NVI6OSEQvF2=
NCI-SNU-16 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HiN2lEPTB;NT62OFA4PCEQvF2=
LU-65 M{nnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjnOId7UUN3ME21Mlc3Ozd|IN88US=>
CW-2 M4nvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTVwOEW5OVkh|ryP
WSU-NHL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\zRYVKSzVyPUWuPVUyPzRizszN
IST-MES1 M364Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqwPZdKSzVyPUWuPVU1PDNizszN
U-266 M{\Pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfBTWM2OD13Lkm4NlAzKM7:TR?=
TALL-1 NGfiOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZwMUS2PFgh|ryP
Calu-6 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHqeXFKSzVyPU[uNVU{OTZizszN
MMAC-SF M4rzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\rS41RUUN3ME22MlE5PTV4IN88US=>
NCI-H82 M4m5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TpNWlEPTB;Nj6yNFQ5QSEQvF2=
RS4-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTZwMkW4PVch|ryP
SNU-C2B NHTicldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7FTWM2OD14LkSwPVY6KM7:TR?=
BOKU MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTvWmJEUUN3ME22MlQ4PTl5IN88US=>
C8166 M2rFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDOTWM2OD14LkW1PVEzKM7:TR?=
D-247MG MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET4boZKSzVyPUeuNFQ{PDdizszN
EW-18 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwMEeyPVIh|ryP
KG-1 M1TvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m5PWlEPTB;Nz62Nlc{QCEQvF2=
REH NXzFSppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCTWM2OD15Lk[4NVA6KM7:TR?=
U-698-M NHS4cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;tUWlEPTB;Nz64OFMyPSEQvF2=
KP-N-RT-BM-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwOUOwNlkh|ryP
MS-1 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPEdJhKSzVyPUeuPVYxPDFizszN
SNU-C1 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XaTGlEPTB;Nz65PFE6OiEQvF2=
SK-MM-2 NVPiXpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO4TpZKSzVyPUiuNlYxPjVizszN
LAN-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnZU4g2UUN3ME24MlMxODBzIN88US=>
NEC8 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;lTWM2OD16LkOwOlkyKM7:TR?=
NCI-H1770 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PxbGlEPTB;OD6zPFAxOiEQvF2=
D-336MG M4DXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\YemZKSzVyPUiuOFAyOTZizszN
COLO-829 NYT5bFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwNEi4O|kh|ryP
LS-513 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH34UWdKSzVyPUiuOVk2QTlizszN
YT NGrvOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HZXmlEPTB;OD62NlQzPyEQvF2=
EW-24 M3TEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPKSYNKSzVyPUiuO|Y2PCEQvF2=
IST-SL1 NV7oV|hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\vTWM2OD16Lki2OVQ{KM7:TR?=
CA46 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRThwOUWwPVgh|ryP
NCI-H1838 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRThwOUi2NFIh|ryP
NCI-H719 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjlemxHUUN3ME25MlI2Ojd7IN88US=>
HCE-T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTlwM{C4OVEh|ryP
A498 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO0VZhKSzVyPUmuN|YyOjRizszN
LB831-BLC M3HOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTlwN{[1NlEh|ryP
SKM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTlwOEW5OlMh|ryP
THP-1 NH3lSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\KNmhmUUN3ME25Mlk3QTF6IN88US=>
SHP-77 NWXr[m86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFyLkSwO{DPxE1?
EW-3 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInsTFZKSzVyPUGwMlYzQDlizszN
KY821 NVPBO5JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLQTWM2OD1zMD63OlMh|ryP
NCI-SNU-1 M1vyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPhTWM2OD1zMT6wNlE4KM7:TR?=
HCC2218 M1y5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFzLkO5PFYh|ryP
IM-9 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF70cHJKSzVyPUGxMlUyODZizszN
NCI-H889 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzxTFFKSzVyPUGxMlU{OTNizszN
HDLM-2 NXzzb4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF{LkSxOVkh|ryP
LB2518-MEL NY\4XplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF{Lk[4NVUh|ryP
NCI-H23 NEfIeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvKVodKSzVyPUGzMlI1OjVizszN
NB17 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjVfGFiUUN3ME2xN{41PTd7IN88US=>
NCI-H322M M3XZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nrT2lEPTB;MUSuOFA3QCEQvF2=
SUP-T1 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XTWM2OD1zND60NVMh|ryP
ES3 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF3LkC3NFMh|ryP
ES5 NXTKfnNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3LkC3PFch|ryP
NCI-H1650 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPNTWM2OD1zNT60PVc6KM7:TR?=
NCI-H226 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3DPJhZUUN3ME2xOU45PzZ6IN88US=>
COR-L88 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK2SHBKSzVyPUG2MlMyPCEQvF2=
SCC-15 NV7MU2FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHifIxEUUN3ME2xOk4{QDZ7IN88US=>
GOTO NFLDO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fpfGlEPTB;MU[uOFc6OyEQvF2=
SIMA NYDUb2xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPYd4VKSzVyPUG2MlQ5ODJizszN
NCI-H1299 NED5T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTV[FlXUUN3ME2xO{4yPTlzIN88US=>
NCI-H1581 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDKR29KSzVyPUG3MlQzOTlizszN
MHH-NB-11 NYDBc|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF5Lkm2PFMh|ryP
MFM-223 NEnsR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\Ud|Z{UUN3ME2xPE4xPTN6IN88US=>
ES7 M4f5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;iS4ZiUUN3ME2xPE42PDNzIN88US=>
JVM-3 NHm1R3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLLRYNKSzVyPUG4MlcyPyEQvF2=
RL NGfKdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LpTGlEPTB;MkCuN|g5KM7:TR?=
EC-GI-10 NUPU[nZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJzLkKwOFEh|ryP
LNCaP-Clone-FGC M1fC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJzLk[3Olgh|ryP
IMR-5 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjCfFlTUUN3ME2yNU45PDl2IN88US=>
KP-N-YS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\GN2lEPTB;MkGuPFc2KM7:TR?=
Mo-T NGfrTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzSUI5NUUN3ME2yNk4zOTh3IN88US=>
NCI-H128 NI\1RZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDyTWM2OD1{Mz61PFU{KM7:TR?=
RH-1 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJ|Lke4OlYh|ryP
NCI-H2171 NXPneG1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17kZ2lEPTB;MkSuNlQ5PSEQvF2=
RPMI-8866 NFTsd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37lVGlEPTB;Mk[uO|QzKM7:TR?=
SK-N-FI MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzaTWM2OD1{Nz6zPFEyKM7:TR?=
LOXIMVI M33leGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPreohKSzVyPUK3MlgxPTFizszN
P31-FUJ MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNzLkWzO|Qh|ryP
KMS-12-PE M4j3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTR7LkWzNFIh|ryP

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (54)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • Zotarolimus(ABT-578)

    Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.

    Features:Zotarolimus has a shorter in vivo half-life and is also demonstrated in rats to have less potent systemic immunosuppression than rapamycin.

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • LY2090314

    LY2090314 は GSK-3α と GSK-3βのために、強力なGSK-3阻害剤で、IC50 がそれぞれ1.5 nM と 0.9 nMです。

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ